CytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line
See more from Benzinga
Cerus Stock Gains As Q2 Earnings Match Expectations, Raises FY21 Sales Guidance
Pacific Biosciences Q2 Earnings Beat Expectations, Higher Operating Costs Widens Quarterly Loss
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.